TransMedics Group, Inc. Common Stock (TMDX) News
Latest headlines that mention TMDX, newest first · each headline opens the original publisher
- Last price
- $65.99
- Day change
- -1.68%
- Next earnings
- 2026-11-05 AMC
TMDX headlines
latest coverageWeill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.
Revenue hit $189.9 million with 21% growth as organ transplant volumes surge.
TransMedics stock slipped on mixed results, but its future remains bright.
Shares are down nearly 45%, but this healthcare innovator may be quietly building the logistics backbone of organ transplantation for decades to come.
Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing sector challenges.
Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead.
TMDX news alerts
Get an alert by email or push when a new headline mentions TMDX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.